Ignite Creation Date:
2024-05-05 @ 5:32 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00479050
Status:
COMPLETED
Last Update Posted:
2007-05-25
First Post:
2007-05-24
Brief Title:
Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
Sponsor:
Shandong University
Organization:
Shandong University
Study Overview
Official Title:
Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TACE-RFA
Brief Summary:
Combined the chemoembolization and Radiofrequency ablation for the hepatocellular carcinoma greater than 3 cmthe ablation volume of coagulation necrosis can be significantly increasedwhich may be enable effective treatment of patients with HCC greater than 3 cm
Detailed Description:
To assess whether the effectiveness of a combination of transcatheter arterial chemoembolizationTACE and radiofrequency ablationRFA is superior to TACE and RFA alone in treatment of patients with hepatocellular carcinomaHCCgreater than 3 cm and to analyze the factors affecting the outcomes
The patients with HCC of 3 or fewer lesions each 3cm greater in diameter entered this randomized controlled trial The primary end point was survival and the secondary end points were tumor response
The patients with HCC of 3 or fewer lesions each 3cm greater in diameter entered this randomized controlled trial The primary end point was survival and the secondary end points were tumor response
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03BS035 | None | None | None |